JP7590010B2 - がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法 - Google Patents

がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法 Download PDF

Info

Publication number
JP7590010B2
JP7590010B2 JP2022550581A JP2022550581A JP7590010B2 JP 7590010 B2 JP7590010 B2 JP 7590010B2 JP 2022550581 A JP2022550581 A JP 2022550581A JP 2022550581 A JP2022550581 A JP 2022550581A JP 7590010 B2 JP7590010 B2 JP 7590010B2
Authority
JP
Japan
Prior art keywords
cells
tumor
hvj
group
apolipoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022550581A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022059703A1 (https=
Inventor
圭祐 二村
亜衣里 石橋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of JPWO2022059703A1 publication Critical patent/JPWO2022059703A1/ja
Application granted granted Critical
Publication of JP7590010B2 publication Critical patent/JP7590010B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18832—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
JP2022550581A 2020-09-16 2021-09-15 がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法 Active JP7590010B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020155901 2020-09-16
JP2020155901 2020-09-16
PCT/JP2021/033925 WO2022059703A1 (ja) 2020-09-16 2021-09-15 がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法

Publications (2)

Publication Number Publication Date
JPWO2022059703A1 JPWO2022059703A1 (https=) 2022-03-24
JP7590010B2 true JP7590010B2 (ja) 2024-11-26

Family

ID=80776709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550581A Active JP7590010B2 (ja) 2020-09-16 2021-09-15 がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法

Country Status (4)

Country Link
US (1) US20230321165A1 (https=)
EP (1) EP4215214A4 (https=)
JP (1) JP7590010B2 (https=)
WO (1) WO2022059703A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025249511A1 (ja) * 2024-05-31 2025-12-04 国立大学法人大阪大学 メッセンジャーｒｎａを腫瘍組織に導入するために用いられる組成物およびがん治療用医薬

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032764A1 (ja) 2008-09-16 2010-03-25 ジェノミディア株式会社 前立腺癌の治療・予防剤
CN103880949A (zh) 2014-03-05 2014-06-25 王家祥 类载脂蛋白c-i及其在制备治疗肾母细胞瘤的药物中的应用
JP2018530624A (ja) 2015-10-19 2018-10-18 コールド ジェネシス， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
WO2019172358A1 (ja) 2018-03-08 2019-09-12 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法
WO2019203497A1 (ko) 2018-04-17 2019-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
WO2019204257A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
JP2020515239A (ja) 2017-04-07 2020-05-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｉｃｏｓアゴニスト抗体およびそれらの使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141598A1 (en) * 1992-08-12 1994-03-03 Tikva Vogel Method of inhibiting cell proliferation using apolipoprotein e
JP3942362B2 (ja) 2000-02-02 2007-07-11 アンジェスＭｇ株式会社 遺伝子導入のためのウイルスエンベロープベクター
CN100532559C (zh) 2000-02-02 2009-08-26 安增子摩祺株式会社 用于基因转移的病毒包膜载体
JP2002065278A (ja) 2000-08-31 2002-03-05 Anges Mg Inc Ｈｖｊの融合タンパク質を含有する遺伝子移入ビヒクル
JPWO2003014338A1 (ja) 2001-08-02 2004-11-25 アンジェスＭｇ株式会社 不活性化ウイルスエンベロープの製造方法
WO2005065720A1 (en) * 2004-01-09 2005-07-21 Mogam Biotechnology Research Institute Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
CA2802388A1 (en) * 2010-06-15 2011-12-22 The Cleveland Clinic Foundation Compositions and methods for treating cancer
WO2013183964A1 (ko) * 2012-06-07 2013-12-12 한양대학교 산학협력단 폐암 진단 및 치료를 위한 표적 단백질
EA038981B1 (ru) * 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
ES2681124B1 (es) * 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010032764A1 (ja) 2008-09-16 2010-03-25 ジェノミディア株式会社 前立腺癌の治療・予防剤
CN103880949A (zh) 2014-03-05 2014-06-25 王家祥 类载脂蛋白c-i及其在制备治疗肾母细胞瘤的药物中的应用
JP2018530624A (ja) 2015-10-19 2018-10-18 コールド ジェネシス， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
JP2020515239A (ja) 2017-04-07 2020-05-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｉｃｏｓアゴニスト抗体およびそれらの使用
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
WO2019172358A1 (ja) 2018-03-08 2019-09-12 国立大学法人 東京大学 Ｈｍｇｎ部分ペプチド及びこれを用いたがん療法
WO2019204257A1 (en) 2018-04-16 2019-10-24 Arrys Therapeutics, Inc. Ep4 inhibitors and use thereof
WO2019203497A1 (ko) 2018-04-17 2019-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Eur. J. Immunol.，2009年，vol.39, issue 2，p.527-540
MATSUSHIMA-MIYAGI, T., et al.，Clin. Cancer. Res.，2012年，vol.18, issue 22，p.6271-6283
日本臨床免疫学会会誌，2005年，vol.28, no.1，p.21-32
黒岡正之ほか，不活化センダイウイルス粒子を用いた抗腫瘍免疫療法の展開，ウイルス，2007年，vol.57, no.1，p.19-28

Also Published As

Publication number Publication date
JPWO2022059703A1 (https=) 2022-03-24
US20230321165A1 (en) 2023-10-12
EP4215214A1 (en) 2023-07-26
WO2022059703A1 (ja) 2022-03-24
EP4215214A4 (en) 2024-07-03

Similar Documents

Publication Publication Date Title
CN109152830B (zh) 用于免疫疗法的核/壳结构平台
JP7038664B2 (ja) 操作された腫瘍溶解性ウイルス
AU2018272085B2 (en) Combination immunotherapies comprising IL-15 superagonists
JP2020169177A (ja) ネオエピトープワクチン組成物及びその使用方法
TWI731095B (zh) 利用前列腺癌相關抗原之腫瘤疫苗接種之組合物及方法
JP6933379B2 (ja) 転移を低減するための方法および組成物
CN110234752A (zh) 用于涉及her2/neu的肿瘤疫苗接种和免疫疗法的组合物和方法
CN107406857A (zh) 用于联合免疫治疗的方法和组合物
CN110831624B (zh) 涉及her抗原的用于肿瘤疫苗接种和免疫疗法的组合物及方法
US20250262293A1 (en) Therapeutic rna for hpv-positive cancer
US20210046177A1 (en) Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
TW202122411A (zh) 以黏液瘤(myxoma)病毒治療癌症之新穎溶瘤病毒平臺
US20260055161A1 (en) Psca car-t cells
EP3941494A1 (en) Compositions and methods for tcr reprogramming using fusion proteins
JP2024514149A (ja) ｕＰＡＲを標的とするＣＡＲ－Ｔ細胞及びその使用
JP7590010B2 (ja) がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法
US20250295746A1 (en) Therapeutic rna for lung cancer
JP2021534786A (ja) 抗腫瘍免疫応答を刺激するキメラ腫瘍溶解性ヘルペスウイルス
CN113453706B (zh) mRNA疫苗
CA3221363A1 (en) Vaccine composition comprising encoded adjuvant
Siddiqui et al. In situ programming of CAR-macrophages via a polyplex nanomaterial and STING activation for triple-negative breast cancer immunotherapy
US12171803B2 (en) Methods of CD40 and toll like receptor immune activation
HK40095244A (zh) 用於hpv阳性癌症的治疗性rna
TW202529780A (zh) 包含抗ｓｔｅａｐ２嵌合抗原受體ｔ細胞之治療組合
HK40110647A (zh) 用於治疗黑素瘤的组合物和方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241107

R150 Certificate of patent or registration of utility model

Ref document number: 7590010

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150